Companies: 10,795·Total market cap: $144.5T
Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd.

ENLVNASDAQHealthcare● Active
$0.71
+$0.00(+0.59%)
Market Cap$17357253
P/E Ratio—
52W High$2.1
52W Low$0.66
Overview
Stock ranking:Biotechnology·Healthcare·View All Market Cap Rankings →

Enlivex Therapeutics Ltd. (ENLV) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · ENLV · as of Jun 9, 2026

Key Statistics

EPS (TTM)$27.02enlv eps ttm · enlv earnings per shareEarnings history
PE Ratio (TTM)0.0×enlv pe ratio ttm · enlv price to earningsPE Ratio deep dive
Revenue (TTM)0.00enlv revenue ttm · enlv annual revenueFull revenue history
Dividend YieldNo Dividenddoes enlv pay dividends · enlv dividend yieldDividend history
Shares Outstanding45.7Menlv shares outstanding · enlv floatShares outstanding history
Next EarningsAug 24, 2026Est.enlv earnings date · enlv next earningsEarnings history

Explore Enlivex Therapeutics Ltd. Data

enlv stock data · financials
Market Cap$17.4Menlv market cap · enlv valuation
Analyst Forecast$15 · Buy
DividendsNo Dividenddoes enlivex therapeutics ltd. pay dividends · enlv dividend yield
Revenue—enlivex therapeutics ltd. annual revenue · enlv revenue
EarningsEPS $27.04+3804.11%enlv earnings · enlv eps
PE Ratio0.0×enlv pe ratio · enlv price to earnings

Financial Snapshot

Full Financials
FY 2025Revenue$0.00
202320242025
enlivex therapeutics ltd. revenue · enlv revenue 2025
FY 2025Net Income$1.24B▲ +8329.17% YoY
202320242025
enlivex therapeutics ltd. net income · enlv profit 2025
FY 2025EPS$27.04▲ +3804.11% YoY
202320242025
enlv eps · enlivex therapeutics ltd. earnings per share 2025
TTM:Revenue: $0.00Net Income: $1.24BEPS: $27.02View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy4 analystsis enlv a buy · enlv analyst rating
Strong Buy
0
Buy
3
Hold
1
Sell
0
Strong Sell
0
12-Month Price Target
$15.00Low
$0.71Current
$15.00Avg Target2000.25% upside
$15.00High
enlv price target · enlv 12 month forecast

Total: 4 · Buy rate: 75.0%

The ENLV analyst consensus is Buy, based on ratings from 4 Wall Street analysts over the past 3 months. The average 12-month price target is $15.00, representing +2000.25% upside from the current price of $0.71.

Stock Performance

Full History
1D+0.59%
1W-13.95%
1M-7.25%
3M-37.35%
YTD+1.56%
1Y-24.02%
5Y-92.22%

About Enlivex Therapeutics Ltd.

CEOOren Hershkovitz
IPO DateJul 31, 2014
Employees71
CountryIL
Websiteenlivex.com

Enlivex Therapeutics Ltd. established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is curre…

BiotechnologyHealthcareNASDAQIL

what is enlivex therapeutics ltd. · enlv stock overview · enlivex therapeutics ltd. company profile · who is enlivex therapeutics ltd. ceo · enlv NASDAQ · enlivex therapeutics ltd. headquarters · enlivex therapeutics ltd. business segments

About Stock Overview & Key Data

Enlivex Therapeutics Ltd. (ENLV) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 31, 2014. As of the latest trading session, ENLV stock price is $0.71, with a market capitalization of $17.4M. The stock has returned -24.02% over the past 12 months and +1.56% year-to-date.

According to 4 Wall Street analysts, the consensus rating for Enlivex Therapeutics Ltd. stock is Buy, with an average 12-month price target of $15.00. In fiscal year 2025, Enlivex Therapeutics Ltd. reported revenue of — and net income of $1.2B. For detailed data — including Enlivex Therapeutics Ltd. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Enlivex Therapeutics Ltd. (ENLV) stock price is $0.71. The stock is traded on NASDAQ under the ticker symbol ENLV. The 52-week range is $0.66 – $2.10.

ENLV stock priceENLV quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice